{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:39:55Z","timestamp":1772725195855,"version":"3.50.1"},"reference-count":38,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"CDC intramural funds and CDC contracts","award":["HCVJCG-2020-45044"],"award-info":[{"award-number":["HCVJCG-2020-45044"]}]},{"name":"CDC intramural funds and CDC contracts","award":["HCVJCG-2022-67978"],"award-info":[{"award-number":["HCVJCG-2022-67978"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1080\/17512433.2026.2632931","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:54:31Z","timestamp":1771350871000},"page":"199-205","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Chelating anticoagulants reduce plasma doxycycline measurements: implications for doxy PEP monitoring"],"prefix":"10.1080","volume":"19","author":[{"given":"Michele B","family":"Daly","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Spandau","sequence":"additional","affiliation":[{"name":"4ES Corporation","place":["San Antonio, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiancheng E","family":"Edwards","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuong","family":"Dinh","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Fountain","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette A.","family":"Dienhart","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Conway-Washington","sequence":"additional","affiliation":[{"name":"Emory University","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Kelley","sequence":"additional","affiliation":[{"name":"Emory University","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Heneine","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Haaland","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention","place":["Atlanta, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"e_1_3_8_2_1","unstructured":"World Health Organization (WHO). Web Annex 1. Key data at a glance. Global progress report on HIV viral hepatitis and sexually transmitted infections 2021. Accountability for the global health sector strategies 2016\u20132021: actions for impact. Geneva: WHO; 2021. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000216"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30725-9"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211934"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7302a1"},{"key":"e_1_3_8_7_1","unstructured":"Doxycycline prophylaxis for prevention of sexually transmitted infections among adolescent and young adult females in the United States. 2024 [cited 2025 Dec 19]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06738407"},{"key":"e_1_3_8_8_1","unstructured":"Randomized directly observed therapy study to interpret clinical trials of doxy-PEP. 2024 [cited 2025 Dec 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06414408"},{"key":"e_1_3_8_9_1","unstructured":"A phase 4 study of a 3-day vs. 7-day regimen of doxycycline for the treatment of chlamydial infection. 2023 [cited 2025 Dec 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05840159"},{"key":"e_1_3_8_10_1","unstructured":"Superiority of on-demand pre-exposure prophylaxis versus post-exposure prophylaxis on using doxycycline for preventing sexually transmitted infections in men who have sex with men. 2023 [cited 2025 Dec 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06188442"},{"key":"e_1_3_8_11_1","unstructured":"A randomized trial of doxycycline chemoprophylaxis for the prevention of sexually transmitted infections in gay bisexual and other men who have sex with men (gbMSM). 2021 [cited 2025 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04762134"},{"key":"e_1_3_8_12_1","unstructured":"Daily doxycycline for early syphillis. 2024 [cited 2025 Dec 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06683638"},{"key":"e_1_3_8_13_1","unstructured":"Daily doxy: study of persons receiving daily doxycycline to inform sexually transmitted infection prophylaxis regimens. 2024 [cited 2025 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06545656"},{"key":"e_1_3_8_14_1","unstructured":"Impact of the daily doxycycline pre-exposure prophylaxis (PrEP) on the incidence of syphilis. Gonorrhoea and chlamydia. 2018 [cited 2025 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03709459"},{"key":"e_1_3_8_15_1","unstructured":"WHO-recommended periodic presumptive treatment versus doxycycline post-exposure prophylaxis for STI control among cisgender men who have sex with men in Kenya. 2024 [cited 2025 Dec 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06468462"},{"key":"e_1_3_8_16_1","unstructured":"STI prophylaxis and emergence of antimicrobial resistance. 2025 [cited 2025 Dec 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06778083"},{"key":"e_1_3_8_17_1","unstructured":"Doxycycline PEP and 4CMenB as a comprehensive prevention strategy in MSM and TGW at high risk for bacterial STIs within the Swiss HIV cohort study. 2024 [cited 2025 Dec 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06242730"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105037"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-3770-4"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250701678955"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1622-1625.2005"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00562453"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238345"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.3.462"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.4.434"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978242233"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000238249"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02157.x"},{"issue":"6","key":"e_1_3_8_30_1","first-page":"991","article-title":"Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia","volume":"35","author":"W\u00f3jcicki J","year":"1985","unstructured":"W\u00f3jcicki J, Kalinowski W, Gawro\u0144ska-Szklarz B. Comparative pharmacokinetics of doxycycline and oxytetracycline in patients with hyperlipidemia. Arzneimittelforschung. 1985;35(6):991\u2013993.","journal-title":"Arzneimittelforschung"},{"issue":"5","key":"e_1_3_8_31_1","first-page":"746","article-title":"Effects of rifampicin on the pharmacokinetics of doxycycline","volume":"35","author":"Garraffo R","year":"1987","unstructured":"Garraffo R, Dellamonica P, Fournier JP, et al. Effects of rifampicin on the pharmacokinetics of doxycycline. Pathol Biol (Paris). 1987;35(5 Pt 2):746\u2013749.","journal-title":"Pathol Biol (Paris)"},{"key":"e_1_3_8_32_1","unstructured":"Mayne Pharma. Doryx (doxycycline hyclate delayed-release tablets) [package insert]. 2013 [cited 2025 Jun 24]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050795s010lbl.pdf"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.26717\/BJSTR.2018.07.001475"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2016.04.009"},{"key":"e_1_3_8_35_1","unstructured":"Combo-PEP: multipurpose prevention of post-exposure prophylaxis regimens. 2021 [cited 2025 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04860505"},{"key":"e_1_3_8_36_1","unstructured":"Doxy-PEP: dose-ranging study of persons receiving doxycycline. 2023 [cited 2025 Dec 10]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05853120"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2020-0187"},{"key":"e_1_3_8_38_1","unstructured":"The HIV Prevention Trials Network. HPTN 091 SSP manual (Version 1.3) section 8: laboratory and specimen management procedures. 2023 [cited 2025 Jun 24]. p. 8\u20131\u20138\u201346. Available from: https:\/\/www.hptn.org\/sites\/default\/files\/inline-files\/HPTN_091_SSP_Version_Control_V1.3_18Apr2023.pdf"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0713"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2026.2632931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:41:50Z","timestamp":1772721710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2026.2632931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1080\/17512433.2026.2632931"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2026.2632931","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}